Clinical Trials Logo
  1. Home
  2. Stargardt Disease
  3. NCT05266014

This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease

Stargardt Disease Clinical Trial

Official title:
Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease

Clinical Trial Summary

Stargardt disease 1 (STGD1) is the most prevalent form of juvenile macular degeneration. It is caused by a rare, inherited autosomal recessive trait, leading to severe and irreversible blindness by the first or second decade of life. Earlier onset of the disease is related to a rapid vision loss, while patients with a later onset tend to have a better prognosis. This study will enrol subjects aged 12-18 years old with a confirmed clinical diagnosis of Stargardt disease type 1 (STGD1). This study will include 2 phases, the phase 1b portion is to determine the optimal dose for phase 2 based on the extent of retinol binding protein 4 (RBP4) reduction after 2 cycles of tinlarebant treatment. The phase 2 portion will evaluate the safety and efficacy of a single daily dose of tinlarebant over a 24-month treatment period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05266014
Study type Interventional
Source RBP4 Pty Ltd
Contact
Status Completed
Phase Phase 1/Phase 2
Start date March 12, 2021
Completion date August 15, 2023
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01676766 - Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease N/A
Enrolling by invitation NCT06048185 - Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
Recruiting NCT04545736 - Oral Metformin for Treatment of ABCA4 Retinopathy Phase 1/Phase 2
Recruiting NCT05674058 - Function and Imaging Assessments for G1961E-associated Stargardt Disease
Recruiting NCT06435000 - An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Completed NCT04909398 - Pupil Dynamics and Color Vision for the Detection of Eye Diseases N/A
Completed NCT02255981 - Efficacy of Acupuncture in Macular Diseases N/A
Recruiting NCT06467344 - Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR) Phase 1/Phase 2
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Recruiting NCT06445322 - Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
Completed NCT05417126 - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease Phase 2
Completed NCT03772665 - Safety and Efficacy of Emixustat in Stargardt Disease Phase 3
Terminated NCT02875704 - Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
Completed NCT03033108 - Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease Phase 2
Recruiting NCT03011541 - Stem Cell Ophthalmology Treatment Study II N/A
Completed NCT02410122 - The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
Enrolling by invitation NCT04239625 - Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) Phase 2
Recruiting NCT05956626 - Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease Phase 1/Phase 2
Recruiting NCT02402660 - Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Phase 2
Completed NCT01977846 - A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies